Ceramide Activated Protein Phosphatases

神经酰胺激活蛋白磷酸酶

基本信息

项目摘要

Ceramide constitutes a family of closely related molecules that function as bioeffector lipids with roles in the regulation of stress responses and growth/death of various human cancer cells. Critical missing elements in our understanding of ceramide stems from the lack of molecularly-defined targets of action and from defining compartment-specific functions of ceramides. Studies in our lab supported by this project have identified ceramide-activated Ser–Thr phosphatases (CAPPs), specifically PP1 and PP2A as direct targets activated by ceramide in vitro. Studies in cells have also shown that various ceramide-inducing stimuli (e.g. TNF, UV, lipotoxic agents) induce dephosphorylation of several substrates in a ceramide-dependent manner. However, not all stimuli induce all dephosphorylations, presumably due to their activation of distinct pathways in distinct subcellular compartments. Recent results have provided us a breakthrough in defining a specific pathway of ceramide generation at the plasma membrane (PM). Here, we will investigate the hypothesis that ceramide generated at the PM acutely activates PP1cα that leads to the dephosphorylation of ezrin and other proteins. This results in a compartment-specific role for ceramide in regulating cell adhesion and migration. We will address these aims: Aim 1. Define a novel pathway of ceramide generation at the PM leading to ezrin dephosphorylation though activation of PP1cα. Here we will investigate the specific hypothesis that PM ceramide regulates a specific form of dimeric PP1c to mediate ezrin dephosphorylation, independent of raft formation. Aim 2. Identify specific cellular programs coupled to compartmentalized ceramide/CAPPs. Here we will investigate the specific hypothesis that PM ceramide, in contrast to ceramide formed in other compartments, regulates cell adhesion and migration. Taken together, these approaches should result, for the first time, in clearly defining a specific, direct, and relevant target for ceramide action (PP1) with a specific function in mediating the effects of PM ceramide on cell adhesion and migration.
神经酰胺构成了一个密切相关的分子家族

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YUSUF AWNI HANNUN其他文献

YUSUF AWNI HANNUN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YUSUF AWNI HANNUN', 18)}}的其他基金

Protein kinase C in Lung Cancer with mutant EGFR
EGFR 突变肺癌中的蛋白激酶 C
  • 批准号:
    10618917
  • 财政年份:
    2020
  • 资助金额:
    $ 35.76万
  • 项目类别:
Protein kinase C in Lung Cancer with mutant EGFR
EGFR 突变肺癌中的蛋白激酶 C
  • 批准号:
    10454776
  • 财政年份:
    2020
  • 资助金额:
    $ 35.76万
  • 项目类别:
Protein kinase C in Lung Cancer with mutant EGFR
EGFR 突变肺癌中的蛋白激酶 C
  • 批准号:
    9888660
  • 财政年份:
    2020
  • 资助金额:
    $ 35.76万
  • 项目类别:
Ceramide Activated Protein Phosphatases
神经酰胺激活蛋白磷酸酶
  • 批准号:
    10208802
  • 财政年份:
    2018
  • 资助金额:
    $ 35.76万
  • 项目类别:
Ceramide Activated Protein Phosphatases
神经酰胺激活蛋白磷酸酶
  • 批准号:
    10734669
  • 财政年份:
    2018
  • 资助金额:
    $ 35.76万
  • 项目类别:
Neutral Sphingomyelinases and Bioactive Ceramides
中性鞘磷脂酶和生物活性神经酰胺
  • 批准号:
    10437811
  • 财政年份:
    2016
  • 资助金额:
    $ 35.76万
  • 项目类别:
Neutral Sphingomyelinases and Bioactive Ceramides
中性鞘磷脂酶和生物活性神经酰胺
  • 批准号:
    10640899
  • 财政年份:
    2016
  • 资助金额:
    $ 35.76万
  • 项目类别:
Neutral sphingomyelinases and bioactive ceramides
中性鞘磷脂酶和生物活性神经酰胺
  • 批准号:
    9071506
  • 财政年份:
    2016
  • 资助金额:
    $ 35.76万
  • 项目类别:
Diversity Supplement for Bernandie Jean: Neutral sphingomyelinases and bioactive ceramides
Bernandie Jean 的多样性补充:中性鞘磷脂酶和生物活性神经酰胺
  • 批准号:
    9752140
  • 财政年份:
    2016
  • 资助金额:
    $ 35.76万
  • 项目类别:
Admin Supplement: Neutral Sphingomyelinases and Bioactive Ceramides
管理补充剂:中性鞘磷脂酶和生物活性神经酰胺
  • 批准号:
    10797322
  • 财政年份:
    2016
  • 资助金额:
    $ 35.76万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 35.76万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了